Autistic people tend to drop out of Medicaid once they reach adulthood in states that don’t waive the income restrictions on enrollment.

The drug clemastine and other compounds that fortify the protective sheath around neurons may prove therapeutic for some genetic neurodevelopmental conditions.

Experiments offer clues to why certain mutations are associated with autism in some people and not others.

New data from clinical trials of arbaclofen and oxytocin underscore the murkiness of null results. Plus, researchers seek clarity on the neurodevelopmental effects of oxytocin during childbirth.

Autistic toddlers who receive a personalized intervention at about 18 months of age gain more abilities than those who start the therapy nine months later.

A shift in astrocyte secretions may explain the atypical firing patterns of neurons derived from people with fragile X syndrome.

Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.

If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.